Literature DB >> 21305359

Treatment of primary aldosteronism: Where are we now?

Asterios Karagiannis1.   

Abstract

Primary aldosteronism (PA) is an important cause of secondary hypertension, is being increasingly diagnosed and may account for more than 10% of hypertensive patients, both in primary care and in referral centers. Aldosterone excess is associated with adverse cardiovascular, renal and metabolic effects that are in part hypertension-independent. Laparoscopic adrenalectomy remains the mainstay of treatment for unilateral forms of PA, whereas medical treatment is recommended for bilateral forms of PA. However, a favourable surgical outcome depends on several factors and many patients are not suitable for this treatment. On the other hand, surgery in patients considered to have bilateral PA may contribute to better blood pressure control. In this review, established and novel strategies for the management of different types of PA are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21305359     DOI: 10.1007/s11154-011-9159-3

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  91 in total

1.  Primary aldosteronism: diagnosis, localization, and treatment.

Authors:  M H Weinberger; C E Grim; J W Hollifield; D C Kem; A Ganguly; N J Kramer; H Y Yune; H Wellman; J P Donohue
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

2.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

3.  Investigation of aldosterone-synthase inhibition in rats.

Authors:  Joël Ménard; Marie-Françoise Gonzalez; Thanh-Tam Guyene; Alvine Bissery
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

4.  Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation.

Authors:  J S Silvestre; V Robert; C Heymes; B Aupetit-Faisant; C Mouas; J M Moalic; B Swynghedauw; C Delcayre
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

5.  Long-term results of endoscopic adrenalectomy for Conn's syndrome.

Authors:  Ines Gockel; A Heintz; M Polta; T Junginger
Journal:  Am Surg       Date:  2007-02       Impact factor: 0.688

6.  High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.

Authors:  Michael Stowasser; Richard D Gordon; Thanuja G Gunasekera; Diane C Cowley; Gregory Ward; Colin Archibald; B Mark Smithers
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

Review 7.  Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.

Authors:  William F Young
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

8.  Efficacy and tolerance of spironolactone in essential hypertension.

Authors:  X Jeunemaitre; G Chatellier; C Kreft-Jais; A Charru; C DeVries; P F Plouin; P Corvol; J Menard
Journal:  Am J Cardiol       Date:  1987-10-01       Impact factor: 2.778

9.  Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.

Authors:  E Born-Frontsberg; M Reincke; L C Rump; S Hahner; S Diederich; R Lorenz; B Allolio; J Seufert; C Schirpenbach; F Beuschlein; M Bidlingmaier; S Endres; M Quinkler
Journal:  J Clin Endocrinol Metab       Date:  2009-02-03       Impact factor: 5.958

10.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

Authors:  M de Gasparo; U Joss; H P Ramjoué; S E Whitebread; H Haenni; L Schenkel; C Kraehenbuehl; M Biollaz; J Grob; J Schmidlin
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

View more
  3 in total

Review 1.  Management of hypertension in primary aldosteronism.

Authors:  Anna Aronova; Thomas J Fahey; Rasa Zarnegar
Journal:  World J Cardiol       Date:  2014-05-26

2.  Screening for Primary Aldosteronism: Whom and How?

Authors:  Michael Doumas; Vasilios Athyros; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-10       Impact factor: 3.738

3.  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Niki Katsiki; Konstantinos Petidis; Apostolos Kamparoudis; Panagiotis Petras; Vasiliki Georgopoulou; Stefanos Finitsis; Christodoulos Papadopoulos; Vasilios G Athyros; Michael Doumas; Asterios Karagiannis
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-05-02       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.